Format

Send to

Choose Destination
Int J Organ Transplant Med. 2017;8(2):110-116. Epub 2017 May 1.

Serum sTWEAK and FGF-23 Levels in Hemodialysis and Renal Transplant Patients.

Author information

1
Department of Clinical Biochemistry and Laboratory Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
2
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
3
Department of Urology, Shahid Modarres Hospital, Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
4
Division of Clinical Laboratory, Children's Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
5
Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Abstract

BACKGROUND:

Kidney transplantation is the treatment of choice for patients with end-stage renal disease.

OBJECTIVE:

To evaluate the changes in serum soluble TNF-like weak inducer of apoptosis (sTWEAK) and fibroblast growth factor 23 (FGF-23) in hemodialysis (HD) patients and renal transplant recipients (RTR).

METHODS:

Serum samples were obtained from 30 patients on chronic HD, 30 RTRs, and 30 normal controls. Biochemical factors, sTWEAK, FGF-23, and interlukin-6 (IL-6) were measured by standard methods.

RESULTS:

Serum levels of sTWEAK in RTRs were significantly higher than those in the HD patients (p=0.025); RTR and HD patients had significantly lower sTWEAK levels than the controls (p=0.001 and p= 0.038, respectively). Serum levels of FGF-23 in HD patients were significantly (p=0.001) higher than those in the RTR; the level was higher in both studied groups compared to that in the controls (p=0.001 for both groups). The mean serum level of IL-6 in HD was significantly higher than that in RTR patients (p=0.013). IL-6 levels in both groups were significantly higher than those in controls (p=0.001 and p= 0.012, respectively). In HD group a negative correlation was found between FGF-23 and sTWEAK (r= 0.375, p=0.041); there were also a significant correlation between FGF-23 and IL-6 (r= 0.480, p= 0.007) and between IL-6 and sTWEAK (r= 0.409, p=0.025).

CONCLUSION:

We found that serum sTWEAK is decreased and FGF-23 is increased in HD and RTR groups comparing with the control group. However, further studies are needed to shed light over their direct role on atherosclerosis and cardiovascular outcomes.

KEYWORDS:

Fibroblast growth factor 23 [Supplementary Concept]; Kidney transplantation; Renal dialysis; TL1 cytokine [Supplementary Concept]; sTWEAK

PMID:
28828171
PMCID:
PMC5549008

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center